The new business development office is located in Massachusetts.
Velesco Pharma, a CDMO, has increased its drug formulation, analytical development, and cGMP clinical-trial manufacturing services with the opening of a new business development office in the greater Boston area.
Velesco will be the first life sciences tenant of the Quincy Center for Innovation (QCI), a 12,500 ft2 facility that provides office space and support services to assist start-up companies. The QCI, located in Quincy Massachusetts, is expected to open fully Sept. 1, 2013.
Source: Velesco Pharma
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING CHALLENGES IN ORAL DELIVERY
February 14th 2025Obesity is a significant global health challenge that requires lifestyle changes and effective pharmacological treatments to overcome. Human glucagon-like peptide 1 (GLP-1) analogs, also called incretin mimetics, have emerged as a promising obesity treatment option. Additionally, oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering greater patient comfort and adherence to expand the therapeutic market.